07:00 , Sep 26, 2011 |  BC Week In Review  |  Company News

Aestus Therapeutics, Astellas deal

Astellas' Prosidion Ltd. subsidiary granted Aestus exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial of the glycogen phosphorylase inhibitor in post-herpetic neuralgia (PHN) by the...
00:58 , Sep 20, 2011 |  BC Extra  |  Company News

Prosidion, Aestus partner for pain compound

Prosidion Ltd. , a subsidiary of Astellas Pharma Inc. (Tokyo:4503), granted Aestus Therapeutics Inc. (North Brunswick, N.J.) exclusive, worldwide rights to develop and commercialize ATx09-002 (formerly PSN357). Aestus plans to begin a Phase II trial...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Clinical News

PSN357: Phase I data

Data from a placebo-controlled, dose-escalation, German Phase I trial in 80 healthy volunteers showed no unexpected safety or pharmacokinetic outcomes for single and multiple-doses of PSN357 daily for 7 days. OSI Pharmaceuticals Inc. (OSIP), Melville,...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Clinical News

PSN357: Phase IIa started

OSIP started a placebo-controlled, dose-escalation, U.S. Phase IIa in up to 30 patients. OSI Pharmaceuticals Inc. (OSIP), Melville, N.Y.   Product: PSN357   Business: Endocrine   Molecular target: Glycogen phosphorylase   Description: Glycogen phosphorylase inhibitor...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Clinical News

PSN357: Phase I started

OSIP started an open-label, dose-escalation Phase I trial in up to 112 healthy volunteers. The study is expected to last about 3 to 6 months. OSI Pharmaceuticals Inc. (OSIP), Melville, N.Y.   Product: PSN357  ...
07:00 , Jun 20, 2005 |  BC Week In Review  |  Clinical News

OSI preclinical data

In a rodent model of diabetes, PSN357 inhibited glycogen phosphorylase and reduced blood glucose levels following acute and chronic dosing. An increase in liver glycogen also was seen in the study, however heart and skeletal...
07:00 , Apr 26, 2004 |  BC Week In Review  |  Company News

OSI endocrine, cancer news

OSIP will invest a further $40 million in its majority-owned subsidiary, Prosidion Ltd. (Oxford, U.K.). The first installment of $10 million has been invested, which brings to 81% OSIP's stake in the company. OSIP formed...
08:00 , Mar 10, 1997 |  BC Week In Review  |  Clinical News

Spectral Diagnostics regulatory update

DIAGF received U.S. Patent No. 5,604,105 for its multiple analyte approach to diagnostics for determining the origins of chest pain. The cardiac markers covered include combinations of Troponin I, Troponin T, myoglobin, CK-MB, glycogen, phosphorylase,...
07:00 , Aug 19, 1996 |  BC Week In Review  |  Clinical News

Spectral Diagnostics regulatory update

DIAGF received notice of allowance for a U.S. patent covering its multiple analyte approach to diagnosing the origins of chest pain. The cardiac markers include Troponin I, Troponin T, glycogen phosphorylase , fatty acid binding...
08:00 , Feb 20, 1996 |  BC Week In Review  |  Company News

Pace Corp., Boehringer Mannheim GmbH deal

Boehringer exercised its option to further collaborate in the development of PACL's cardiac diagnostic tests based on Glycogen Phosphorylase BB (see BioCentury Oct. 16). PACL will receive royalties, and may manufacture its own line of...